The first new treatments for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the battle against superbug strains of the pathogen, according to scientists.
Gonorrhoea infections are increasing worldwide, with data suggesting more than 82 million instances per year. Notably increased rates are observed in the African continent and nations within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. Across England, cases have reached a all-time high, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.
“The approval of new treatments for gonorrhoea is an important and timely development in the context of increasing worldwide cases, the spread of superbugs and the very limited treatment choices at this time.”
Health officials are deeply concerned about the surge in treatment-resistant strains. The World Health Organization has classified it as a "critical concern". Ongoing monitoring revealed that resistance to key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.
Zoliflodacin, also known as Nuzolvence, was approved by the US Food and Drug Administration in December for combating gonorrhoea. This infection can lead to major issues, including infertility. Experts believe that targeted use of this new drug will help delay the spread of drug resistance.
Gepotidacin, developed by the pharmaceutical company GSK, was also approved in the same week. This medication, which is additionally indicated for UTIs, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.
This new treatment emerged from a new, not-for-profit approach for antibiotic development. The charitable organization GARDP collaborated with the drug firm its industry partner to see it through.
“This authorization marks a major breakthrough in the management of highly resistant gonorrhoea, which previously has been evolving faster than medical innovation.”
As per results published in a prominent scientific publication, zoliflodacin eradicated more than 90% of uncomplicated infections. This places it at an similar efficacy with the current standard treatment, which uses an injection and a pill. The research enrolled over 900 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.
Under the terms of its development partnership, the non-profit has the ability to register and commercialise the drug in a wide range of developing nations.
Doctors on the front lines have expressed hope. Having a easy-to-administer therapy like this is seen as a "game-changer" for gonorrhoea control. This is viewed as essential to reduce the burden of the disease for individuals and to stop the proliferation of extremely resistant gonorrhoea around the world.
A seasoned software engineer with a passion for open-source projects and tech education.
